CliffBio
small molecule

SUCLEAR

MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

Loss of exclusivity—loss of exclusivity
CompanyBraintree →See this company's full patent-cliff portfolio

Drug detail

Brand nameSUCLEAR
Active ingredientMAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE
Strength1.6GM/BOT,3.13GM/BOT,17.5GM/BOT,N/A,N/A,N/A,N/A;N/A,N/A,N/A,210GM,0.74GM,2.86GM,5.6GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formSOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalJanuary 2013
Marketing statusDISCN

More from Braintree

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

SUCLEAR patent cliff — loss of exclusivity — | CliffBio